Boehringer Ingelheim
Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure
April 20, 2016Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly
Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …
Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business
April 20, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results
Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …
Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials
April 13, 2016Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …
Former US CEO of Boehringer Ingelheim becomes chairman at Inotek Pharmaceuticals
April 11, 2016Medical Communications Boehringer Ingelheim, inotek, inotek pharma, j martin carroll
Inotek Pharmaceuticals has announced the appointment of J. Martin Carroll as the new chairman of the board. Carroll will succeed …
Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication
April 7, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …
AbbVie pays $595m upfront for experimental Boehringer psoriasis drug
March 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, BI 655066, Boehringer Ingelheim, psoriasis
AbbVie is betting big on the future of an experimental psoriasis drug, paying $595m upfront for the rights to Boehringer …
Boehringer launches IPF initiatives
February 29, 2016Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev
Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …
Boehringer’s OFEV slows IPF disease progression by half in trials
February 26, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev
Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …
FDA reviews Jardiance as cardiovascular diabetes treatment
January 27, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance
The FDA has accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for their diabetes drug Jardiance to be …
Boehringer Ingelheim invests in Europe
December 24, 2015Manufacturing and Production, Sales and Marketing Austria, Biberach, Boehringer Ingelheim, Vienna, biologicals, manufacturing, production
Boehringer Ingelheim will kick off its pharma investments in 2016 with a half a billion Euro outlay and plans to …
FDA approves Lilly/Boehringer Lantus biosimilar
December 17, 2015Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly
The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …
Pharma giants Sanofi and Boehringer negotiate deal to swap assets
December 15, 2015Business Services, Manufacturing and Production, Sales and Marketing Andreas Barner, Boehringer, Boehringer Ingelheim, Merial, Sanofi, olivier brandicourt
Two of the world’s biggest pharma companies – Sanofi and Boehringer Ingelheim – have entered into exclusive negotiations to swap …
Boehringer cuts R&D budget to €11bn to focus on collaborations
November 13, 2015Medical Communications, Research and Development Boehringer Ingelheim
Boehringer Ingelheim has launched its new research and development strategy, committing €11 billion to R&D over the next five years. …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
FDA approves Boehringer’s Pradaxa reversal agent
October 19, 2015Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab
The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
